Search Blog
Categories
April 2019
M T W T F S S
« Mar    
1234567
891011121314
15161718192021
22232425262728
2930  

Tags

CLASS ACTION UPDATE for BV, CRBP and MWA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

ACCESSWIRE

By Levi & Korsinsky, LLP

NEW YORK, NY / ACCESSWIRE / April 17, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

BrightView Holdings, Inc. (NYSE: BV)

Class Period: Purchasers of common stock pursuant to the IPO completed around July 2, 2018
Lead Plaintiff Deadline : June 14, 2019
Join the action: https://www.zlk.com/pslra-1/brightview-holdings-inc-loss-form?prid=1153&wire=1

The complaint alleges that the defendants made materially false and/or misleading statements in the Offering Documents relating to the IPO, including omitting or failing to disclose that: (i) a material portion of BrightView’s contracts were underperforming and/or represented undesirable costs to the Company; (ii) as a result of the foregoing, BrightView would implement a “managed exit” strategy to end its low margin and non-profitable contracts with customers; (iii) this “managed exit” strategy would negatively impact BrightView’s future revenue throughout 2018, and would continue to do so well into fiscal year 2019; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.

To learn more about the BrightView Holdings, Inc. class action contact jlevi@levikorsinsky.com.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQGM: CRBP)

Class Period: November 14, 2016 – February 28, 2019
Lead Plaintiff Deadline : May 13, 2019
Join the action: https://www.zlk.com/pslra-1/corbus-pharmaceutical-holdings-inc-loss-form?prid=1153&wire=1

The lawsuit alleges: Corbus Pharmaceuticals Holdings, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about the Corbus Pharmaceuticals Holdings, Inc. class action contact jlevi@levikorsinsky.com.

Mueller Water Products, Inc. (NYSE: MWA)

Class Period: May 9, 2016 – August 6, 2018
Lead Plaintiff Deadline : June 10, 2019
Join the action: https://www.zlk.com/pslra-1/mueller-water-products-inc-loss-form?prid=1153&wire=1

The lawsuit alleges that, during the class period, Mueller Water Products, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate testing for product quality; (2) certain products with radio components were susceptible to fail prematurely; (3) as a result, the Company was reasonably likely to incur increased expenses, including warranty costs; (4) these costs would materially impact the Company’s financial statements; (5) the Company lacked adequate internal controls over warranty costs and estimates; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the Mueller Water Products, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 542302